Author:
Vázquez-Sánchez Rocío,Diez-Fernández Raúl,Enrech-Frances Santos,Sánchez-Peña Ana,Molina-García Teresa
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy
Reference10 articles.
1. D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23:2926–36.
2. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847–57.
3. Castria TB, da Silva EMK, Gois AFT, Riera R. Cisplatin versus carboplatin in combination with third generation drugs for advanced non-small cell lung cancer (Review). Cochrane Database Syst Rev. 2013;8:CD009256.
4. Provencio M, de Las Peñas R, Camps C, Artal A, Massuti B, Cobo M, et al. Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: is a hemogram on day 8 essential? Lung Cancer. 2010;68:415–9.
5. Provencio M, Sánchez A, Artal A, Sánchez Torres JM, García Gómez R, Constenla M, et al. Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary. Clin Transl Oncol. 2013;15:659–64.